Tolerability of atypical neuroleptics and acetylcholinesterase inhibitors when treating neuropsychiatric symptoms in Parkinson's disease

References

• Van Den Eeden S, Tanner C, Bernstein A, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015–1022.
   PubMed Web of Science ®Google Scholar
• Miyasaki J. Evidence-based initiation of dopaminergic therapy in Parkinson’s disease. Neurology. 2010;257 Suppl 2:S309–S313.
   Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52:784–788.
   PubMed Web of Science ®Google Scholar
• Reichmann H, Schneider C, Lohle M. Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism Relat Disord. 2009; 15 Suppl 3:S87–S92.
   Google Scholar
• Rabey J. Hallucinations and psychosis in Parkinson’s disease. Parkinsonism RelatDisord. 2009;15 Suppl 3:S105–S110.
   Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24:2175–2186.
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V et al. Practice parameters: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996–1002.
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomized, double-blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:903–904.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. NEngl J Med. 2004;351:2509–2518.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708–712.
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–2036.
   PubMed Web of Science ®Google Scholar
• van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther. 2011;17:428–441.
   PubMed Web of Science ®Google Scholar
• Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. JPsychiatr Pract. 2007;13:13–24.
   PubMedGoogle Scholar
• French Clozapine Study Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease.. Lancet. 1999;353:2041–2042.
   Web of Science ®Google Scholar
• Pollack P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689–695.
   Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–763.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson’s Disease. Ther Adv Neurol Disord. 2010;3:339–350.
   PubMedGoogle Scholar
• Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52:438–445.
   PubMed Web of Science ®Google Scholar
• Ondo W, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031–1035.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6):789–794.
   PubMed Web of Science ®Google Scholar
• Schneider L, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s Disease. N Engl J Med. 2006;355:1525–1538.
   PubMed Web of Science ®Google Scholar
• Daumit G, Goff D, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105:175–187.
   PubMed Web of Science ®Google Scholar
• Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166:1063–1064.
   Web of Science ®Google Scholar
• Schneider L, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blinded olanzapine trial. Neuropsychopharmacology. 1996;14:111–123.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Rosenquist KJ, Pardo TB, Goodwin FK. Extrapyramidal side effects with atypical antipsychotics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30: 209–213.
   PubMed Web of Science ®Google Scholar
• Hu Y, Lu Y, Yu W, et al. Long-term retention rate of topiramate as initial monotherapy in Chinese patients with newly diagnosed epilepsy: a prospective, observational study. Epilepsy Res. 2010;90:278–284.
   Web of Science ®Google Scholar
• Yuen AW, Singh R, Bell GS, et al. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res. 2009;87:120–123.
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol. 2010;67:408–415.
   PubMedGoogle Scholar
• Carpay JA, Aalbers K, Graveland GA, Engelsman M. Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy. Seizure. 2009;18:119–123.
   Web of Science ®Google Scholar